Search company, investor...

Predict your next investment

Corporation
mainzsolutions.com

About Mainz

Mainz is a technology-enabled company that works with clients to transform and align their employee and customer experiences. Delivering their proprietary Recruiting as a Service (RaaS) product, Mainz uses predictive technology and state-of-the-art assessment tools to dramatically reduce conventional pain points associated with discovering and hiring optimal talent. From entry-level hires to C-Suite appointments, Mainz empowers organizations of all kinds with their recruiting solutions, helping to impact their business performance with exceptional, custom-suited talent.

Headquarters Location

381 Park Avenue South Suite 721

New York, New York, 10016,

United States

347-334-5820

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest Mainz News

Mainz Biomed and Praxisdienst Form Distribution Alliance for ColoAlert

Feb 23, 2024

BERKELEY, US – MAINZ, Germany – February 23rd, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, is pleased to announce a distribution partnership with Praxisdienst, Germany’s largest online retailer for medical products. This collaboration, which commenced in February 2024, marks an important step in Mainz Biomed’s mission to enhance healthcare delivery across Germany, focusing on the accessibility of their flagship product, ColoAlert®. ColoAlert® represents a breakthrough in the early detection of colorectal cancer, offering a convenient, non-invasive at-home stool test that goes beyond traditional screening methods. Unlike standard tests that only detect the presence of blood in the stool, ColoAlert® utilizes advanced technology to identify tumor DNA, providing a more comprehensive screening option. This innovative approach ensures higher detection rates, especially in cases where tumors do not bleed, thereby facilitating the early diagnosis of colorectal cancer. Early detection is crucial, as it significantly enhances the treatability of this condition, potentially saving lives. Praxisdienst, has consistently demonstrated its capacity for innovation and leadership in the medical products market. Praxisdienst’s achievements, including the “Deutscher Gesundheits-Award 2022” in the “Medical Technology – Online Shops” category and its recognition as a Top Innovator in 2023, highlight its dedication to excellence and innovation. This partnership will harness Praxisdienst’s extensive distribution network alongside Mainz Biomed’s leading-edge diagnostic technologies, ensuring broader access to their sophisticated medical solutions for healthcare professionals and patients throughout Germany. Darin Leigh, CCO of Mainz Biomed, expressed enthusiasm about the partnership: “We are delighted to partner with Praxisdienst to distribute ColoAlert®, our innovative at-home screening test for colorectal cancer. This collaboration is not only in line with our strategic objectives but also underscores our commitment to providing superior diagnostic solutions to the healthcare sector. We are confident that this partnership will have a profound impact on healthcare standards and patient care in Germany by making early detection of colorectal cancer more accessible.”

Mainz Acquisitions

1 Acquisition

Mainz acquired 1 company. Their latest acquisition was Tricor Staffing on February 24, 2016.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

2/24/2016

$99M

Acquired

1

Date

2/24/2016

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acquired

Sources

1

Mainz Team

1 Team Member

Mainz has 1 team member, including former Founder, Joshua Sason.

Name

Work History

Title

Status

Joshua Sason

Founder

Former

Name

Joshua Sason

Work History

Title

Founder

Status

Former

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.